MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today announced that its Affirm® Contrast Biopsy Software, which combines contrast-enhanced diagnostic ...
Hologic has paid $64 million to buy a German biopsy health technology firm, the Marlborough medical device maker said Monday, giving it the second acquisition of roughly that size in the past five ...
A new private-label deal will see Hologic Inc. distributing a soft tissue biopsy instrument manufactured by Angiotech Pharmaceuticals Inc. Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) inked a three-year ...
Hologic (HOLX) announced that its Affirm Contrast Biopsy Software, which combines contrast-enhanced diagnostic capabilities with accurate lesion targeting to help streamline workflow and accelerate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback